VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | ClarIDHy: ivosidenib in CCA

Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, outlines novel targeted therapies in cholangiocarcinoma (CCA). Specifically discussed is results from the Phase III ClarIDHy study (NCT02989857), evaluating ivosidenib in IDH1-mutant, chemotherapy-refractory CCA. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter